Osi Pharmaceuticals, Inc.

Probiodrug

Kerstin Kühn-Wache

Hans-Ulrich Demuth

Torsten Hoffmann

Ulrich Heiser

Fred Rosche

Joachim Bär

Wolfgang Brandt

The present application relates to the secondary binding site of dipeptidyl peptidase IV, its relationship amongst substrates and to the modulation of substrate specificity of dipeptidyl peptidase IV (DP IV, synonym: DPP IV, CD26, EC 3.4.14.5). The application relates further to compounds that bind to the secondary binding site of DP IV and their use to modulate the substrate specificity of DP IV; methods of treatment of various DP IV mediated disorders; and screening methods for the identification of secondary binding sites on DP IV and DP IV-like enzymes.

Secondary binding site of dipeptidyl peptidase IV (DP IV)

A method of raising the blood sugar level in a mammal having hypoglycemia is described. The method reduces degradation of glucagon by administering to the mammal a therapeutically effective amount of an inhibitor of dipeptidyl peptidase IV and physiologically acceptable adjuvants and/or excipients.

Raising blood sugar level in hypoglycemic mammals by administering inhibitors of dipeptidyl peptidase IV

Growing community of inventors

Halle/Saale, Germany

Kerstin Kühn-Wache